International Vaccine Institute and Bharat Biotech launch Phase II and III trials for chikungunya vaccine

Source: Indian Express

What is the news?

A multi-country Phase II / III clinical trial of a vaccine led by the International Vaccine Institute (IVI) in partnership with Bharat Biotech International Ltd (BBIL) has begun in Costa Rica.

Read more: World may soon get a vaccine against Chikungunya

What is Chikungunya?

It is a viral disease transmitted to humans by infected mosquitoes

How is it transmitted?

Chikungunya virus is most often spread to people by Aedes aegypti and Aedes albopictus mosquitoes. These are the same mosquitoes that transmit the dengue virus.


  • The most common symptoms of infection are fever and joint pain
  • Other symptoms may include headache, muscle pain, joint swelling, or rash.

Vaccination: Presently, there is no vaccine to prevent or medicine to treat Chikungunya virus infection.

Print Friendly and PDF